Biomea Fusion Prices $25M Public Offering for Diabetes, Obesity Treatments
Biomea Fusion, Inc. (Nasdaq: BMEA) has priced its public offering at approximately $25.0 million. The offering, set to close on October 8, 2025, is led by Jefferies LLC as the sole bookrunner, with H.C. Wainwright & Co. acting as lead manager. The company aims to deliver transformative treatments for diabetes, obesity, and related conditions.
Biomea Fusion, a clinical-stage diabetes and obesity company, is offering 11,195,121 shares of common stock and accompanying warrants. The combined offering price per share and warrant is $2.05. The offering is conducted pursuant to an effective shelf registration statement on Form S-3 filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus can be obtained from Jefferies LLC or the SEC's website. The offering includes an option for underwriters to purchase additional shares and/or warrants.
Jefferies LLC, acting as the sole bookrunner, is representing itself in the stock issuance. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities in any jurisdiction where such an offer or solicitation would be unlawful.
Biomea Fusion's public offering, priced at approximately $25.0 million, is expected to close on October 8, 2025, subject to customary closing conditions. The company's mission to deliver transformative treatments for diabetes and obesity is supported by this funding, with the offering led by Jefferies LLC and H.C. Wainwright & Co.
Read also:
- Thieves Steal Unique Sculptures from Redwood National Park's Grove of Titans
- Stellantis Pivots US Strategy: Drops Electric Dodge Charger, Embraces V8s
- Thessaly's Climate Plan Stalls Two Years After Storm Daniel Devastation
- Strategizing the Integration of Digital Menus as a Core Element in Business Operations
